Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety
Sean K. Kelley, Louise A. Harris, David Xie, Laura DeForge, Klara Totpal, Jeanine Bussiere and Judith A. Fox
Journal of Pharmacology and Experimental Therapeutics October 2001, 299 (1) 31-38;
Sean K. Kelley
Louise A. Harris
David Xie
Laura DeForge
Klara Totpal
Jeanine Bussiere
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Journal of Pharmacology and Experimental Therapeutics
Vol. 299, Issue 1
1 Oct 2001
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety
Sean K. Kelley, Louise A. Harris, David Xie, Laura DeForge, Klara Totpal, Jeanine Bussiere and Judith A. Fox
Journal of Pharmacology and Experimental Therapeutics October 1, 2001, 299 (1) 31-38;
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety
Sean K. Kelley, Louise A. Harris, David Xie, Laura DeForge, Klara Totpal, Jeanine Bussiere and Judith A. Fox
Journal of Pharmacology and Experimental Therapeutics October 1, 2001, 299 (1) 31-38;
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement